A deep monitoring microfluidic platform for label-free identification and nanodrug evaluation in lung cancer.
Abstract
Real-time detection of rare cancer cells holds potential for guiding more informed treatment decisions at the bedside. However, conventional enrichment methods are limited by low sensitivity, a high risk of cell damage, and prolonged processing times. To address these challenges, this study developed an intelligent micro-total analysis platform toward H1299 cells (a metastatic non-small cell lung cancer cell line). The system integrates a cascaded dual-microfluidic chip architecture with a high-resolution microscope driven by a deep learning-based detection framework. Finite element simulations were performed to optimize droplet generation conditions for the cross-junction microfluidic chip. A dataset of 749 high-resolution droplet images (1536 × 1024 pixels) was constructed, comprising 2619 live H1299 lung cancer cells distributed across 5127 droplets. Among the algorithms evaluated, the YOLOv7 model was selected and optimized, achieving a detection accuracy above 98% and a real-time inference speed exceeding 55 frames per second. As a proof of concept, the platform was applied to quantitatively analyze single-cell level responses to anticancer drugs in undiluted whole blood and processed biopsy samples within 30-40 min, yielding results consistent with those of the standard Cell Counting Kit-8 (CCK-8) assay. The minimal sample requirement, label-free operation, and stable performance of the system underscore its potential for treatment monitoring. Moreover, its capacity for continuous image acquisition and autonomous analysis may facilitate dynamic monitoring in future cancer research.